FSH
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- Rising FSH is the earliest and most reliable laboratory signal of ovarian aging — often detectable years before cycle irregularity or estrogen decline. As ovarian follicular reserve diminishes with age, inhibin B production falls, removing the primary suppressor of FSH. The pituitary responds by escalating FSH output. Day 3 FSH monitoring in women who are tracking their reproductive or hormonal health can detect this trajectory years before conventional menopause workup would be triggered.
- FSH distinguishes primary from secondary gonadal failure — a distinction that changes the entire clinical pathway. Primary gonadal failure (ovaries or testes failing to respond) produces high FSH as the pituitary escalates stimulation. Secondary gonadal failure (pituitary or hypothalamus failing to signal) produces low or inappropriately normal FSH despite low sex hormones. In men: high FSH + low testosterone = primary hypogonadism (testicular failure). Low FSH + low testosterone = secondary hypogonadism (pituitary problem, possibly a prolactinoma). This distinction determines whether fertility-preserving treatment options (clomiphene, gonadotropins) are viable.
- FSH variability in perimenopause is high — a single measurement can be misleading. During the perimenopause transition, FSH fluctuates dramatically cycle to cycle. A woman may have FSH of 8 mIU/mL one month and 28 mIU/mL two months later. This variability is itself a sign of perimenopause — the regulatory system is destabilizing. Serial measurements over 3–6 months give a more accurate picture than any single value. The trend (rising) matters more than any individual number during this phase.
- AMH (anti-Müllerian hormone) has largely replaced FSH as the primary marker of ovarian reserve in fertility medicine — but FSH remains the more accessible and interpretable test for most longevity contexts. AMH is more stable across the menstrual cycle (can be drawn on any day), more sensitive at low levels, and better at predicting ovarian response to stimulation. However, FSH is included in most standard hormonal panels, is well-standardized, and provides immediately interpretable information about the HPG axis regulatory state. For fertility-focused assessment, AMH is the preferred marker. For understanding whether ovarian function is the source of hormonal symptoms in a perimenopausal woman, FSH provides sufficient information.
- In men, FSH is the key missing piece in most testosterone workups. A complete male hypogonadism workup requires FSH and LH alongside testosterone — yet many clinicians order only total testosterone. Without FSH and LH, distinguishing primary from secondary hypogonadism is impossible from blood tests. This distinction has major clinical implications: a man with primary hypogonadism is unlikely to respond to clomiphene or pulsatile GnRH therapy, while a man with secondary hypogonadism may have excellent response.
The HPG Axis: Why FSH Is the Signal, Not Just a Number
FSH doesn't rise in isolation — it rises because something downstream has changed. Understanding why requires a brief map of the hypothalamic-pituitary-gonadal (HPG) axis, the regulatory system that controls sex hormone production in both sexes.
The hypothalamus releases GnRH in pulses. GnRH stimulates the pituitary to release FSH and LH. In women, FSH drives follicular development, which produces estrogen and inhibin B. Estrogen and inhibin B feed back to the pituitary to suppress FSH as the follicle matures. In men, FSH drives spermatogenesis, and inhibin B produced by Sertoli cells provides the primary negative feedback on FSH.
When the gonads age and produce less inhibin B — because fewer follicles remain in the ovaries, or because Sertoli cell function declines in the testes — the primary brake on FSH is reduced. The pituitary responds by escalating FSH output, attempting to compensate for declining gonadal responsiveness. This is why rising FSH is such a reliable signal of gonadal aging: it is a direct readout of the pituitary's increasingly desperate attempt to stimulate organs that are becoming progressively less responsive.
FSH in Perimenopause: Years Earlier Than Most Women Expect
The average age of menopause (final menstrual period) in the United States is 51. The perimenopausal transition, defined as the period of hormonal fluctuation preceding menopause, lasts on average 4–8 years. But hormonal changes detectable by testing can begin substantially earlier.
Studies using day 3 FSH measurements in women with regular cycles have found that FSH begins rising meaningfully, on average, in a woman's late 30s — often at age 37–38. By the mid-40s, FSH is rising in the majority of women even in those who still have regular cycles and no subjective symptoms. By the late 40s, FSH variability becomes extreme — the cycle-to-cycle swings that characterize the perimenopause transition are underway.
This means that FSH testing in women in their late 30s and early 40s who are proactively monitoring hormonal health can detect the trajectory of ovarian aging years before symptoms develop. This early visibility is valuable not because it changes what is biologically happening, but because it informs timing decisions around hormonal optimization, fertility planning, bone density monitoring, and cardiovascular risk management. 1
| Population / Phase | Standard Range | Longevity Optimal | Notes |
|---|---|---|---|
| Women — day 3 (reproductive) | 3.5–12.5 mIU/mL | 3–8 mIU/mL | Above 10 suggests diminished ovarian reserve |
| Women — perimenopausal | Highly variable | Track trend, not single value | Variability itself signals transition |
| Women — postmenopausal | 25–135 mIU/mL | N/A — expected elevation | Confirms ovarian failure |
| Men | 1.5–12.4 mIU/mL | 2–7 mIU/mL | Elevated = primary testicular failure |
| Range Type | Value (mIU/mL) | Notes |
|---|---|---|
| Standard Clinical Range | Women — follicular phase: 3.5–12.5 mIU/mL · Women — perimenopausal: > 12 mIU/mL variable · Women — postmenopausal: 25–135 mIU/mL · Men: 1.5–12.4 mIU/mL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | Women (reproductive age, follicular phase): 3–8 mIU/mL · Men: 2–7 mIU/mL |
Associated with reduced all-cause mortality and extended healthspan.
FSH interpretation depends heavily on age, menstrual cycle phase, and clinical context. In premenopausal women, a mid-follicular (day 2–3) FSH above 10 mIU/mL indicates diminished ovarian reserve; above 15 mIU/mL significantly impairs fertility; above 25–30 mIU/mL suggests perimenopause or premature ovarian insufficiency. In perimenopausal women, FSH is highly variable cycle to cycle and a single measurement is less informative than a trend. FSH must be drawn on day 2–3 of the menstrual cycle for ovarian reserve assessment. In postmenopausal women, FSH is persistently elevated (typically > 30–40 mIU/mL). In men, a high FSH combined with low testosterone indicates primary hypogonadism (testicular origin); a low FSH with low testosterone indicates secondary hypogonadism (pituitary/hypothalamic origin).
|
Already have your results? See what your FSH and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
When should women test FSH, and what cycle day matters?
For ovarian reserve assessment — determining how much follicular reserve remains and whether FSH is rising with age — the test must be drawn on day 2 or day 3 of the menstrual cycle (day 1 being the first day of full menstrual flow). This early follicular phase timing is when FSH is being driven by the pituitary to recruit follicles for the upcoming cycle, providing the best window into how hard the pituitary is working to stimulate the ovaries. A day 3 FSH drawn at this time is the standard measure for ovarian reserve. FSH drawn at other cycle phases is not interpretable for ovarian reserve — mid-cycle FSH surges to trigger ovulation (the LH/FSH surge), and luteal phase FSH has been suppressed by progesterone and estrogen. If drawn at the wrong time, FSH can appear falsely normal or falsely elevated. For women whose cycles are irregular or absent (perimenopause, hypothalamic amenorrhea), timing by cycle day isn't possible — in this context, FSH is drawn with estradiol on any day and interpreted based on the combined picture.
What FSH level indicates menopause?
Menopause is clinically defined as 12 consecutive months without a menstrual period, not by any single hormone level. That said, a fasting FSH above 30–40 mIU/mL combined with appropriate symptoms and absence of periods strongly suggests ovarian failure consistent with menopause. Because FSH fluctuates significantly in perimenopause, a single elevated FSH does not confirm menopause — the 12-month amenorrhea criterion remains the clinical standard. In women who have had a hysterectomy (so period cessation can't be used as a marker), FSH above 30 mIU/mL in combination with symptoms and elevated LH is used to confirm menopausal status. For women on hormonal contraception, FSH is suppressed by exogenous hormones and is not interpretable for menopausal staging while on contraception.
Can FSH be used to determine if hormone therapy is appropriate for perimenopausal symptoms?
FSH provides useful supporting evidence, but is not the sole determinant of whether hormone therapy is appropriate. A perimenopausal woman with vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, and other transition symptoms may benefit from hormone therapy regardless of whether FSH is mildly or significantly elevated — the symptom burden is the primary driver of the treatment decision. That said, knowing FSH is rising helps confirm that symptoms are driven by ovarian aging rather than other causes, and informs the type of hormonal support most likely to be useful (estrogen versus progesterone versus both). FSH tracking over time — watching it rise — also helps time hormone therapy initiation and understand the trajectory of the transition.
Why would a man have elevated FSH?
In men, elevated FSH almost always indicates primary testicular failure — the testes are not producing adequate sperm or hormones, and the pituitary is escalating FSH production in a futile attempt to drive spermatogenesis. Common causes include Klinefelter syndrome (XXY karyotype, the most common genetic cause), prior chemotherapy or radiation to the testes, bilateral undescended testes, testicular torsion or trauma, severe varicocele, orchitis (testicular infection), and age-related testicular decline. A man with elevated FSH and low sperm count or low testosterone should receive endocrinology or reproductive urology evaluation. Importantly, elevated FSH indicates that sperm production capacity at the testicular level is compromised — treatments that work by stimulating the pituitary or hypothalamus (clomiphene, GnRH analogues) are unlikely to be effective in primary testicular failure, though intralesional sperm retrieval may still be possible in some cases.